Morbidity, mortality and long term survival in patients with vascular resection in pancreatic cancer – single center experience

Rok, strany: 2017, 460 - 463

Although venous resection in pancreatic cancer is widely used method, recently published data about its safety and survival benefit showed conflicting results. A retrospective case matched study was performed to compare the results of patients who underwent venous resection to those with no venous resection during radical surgery in pancreatic cancer.From January 2010 to December 2015, 297 pancreatic resections due to pancreatic tumor were performed in the National Cancer Institute (NCI). Fifty-three patients with venous resection were identified and enrolled into the study and matched with 66 patients without vascular resection during radical resection of pancreatic head/body cancer. Both groups matched for age, ASA score, need for preoperative biliary drainage and clinical staging of the tumor. Morbidity was determined according Clavien and Dindo classification [1] and was similar in both groups of patients (p = 0.48). Thirty day postoperative mortality was also equal in both groups 5.6 vs 4.5% (p > 0.99) and long term survival was with no significant difference. Median overall survival was 18.8 vs 20.7 months (p = 0.33) for patients with/without venous resection.Therefore we consider venous resection in pancreatic cancer safe procedure with equal morbidity and perioperative mortality as in patients with no need for vascular resection and with the same long term survival if R0 resection is achieved. Keywords: pancreas, neoplasm, morbidity, mortality

ISO 690:

Pindak, D., Tomas, M., Dolnik, J., Duchon, R., Pavlendova, J. 2017. Morbidity, mortality and long term survival in patients with vascular resection in pancreatic cancer – single center experience. In NEOPLASMA, vol. 64, no.3, pp. 460-463. 0028-2685.

APA:

Pindak, D., Tomas, M., Dolnik, J., Duchon, R., Pavlendova, J. (2017). Morbidity, mortality and long term survival in patients with vascular resection in pancreatic cancer – single center experience. NEOPLASMA, 64(3), 460-463. 0028-2685.